Simeka aims to establish a diversified healthcare portfolio with revenues of R2,5 billion by 2021 and R5 billion by 2025.

Specpharm is a South African based pharmaceutical company which was established in April 2007. The company’s head office is in Midrand, Gauteng Province. It has two core business areas:

  • The first primary business area is a manufacturing facility, where it manufactures and packages innovator and generic products for third party customers
  • The second is the commercial business area where the company markets and sells generic and innovator products into South Africa and neighbouring countries

Specpharm prides itself in its consistent delivery of high quality products (original brands and generics), and ensures that all partners are audited and meet the high standards required by the Pharmaceutical Inspection Convention Scheme (PICS). Specpharm has made significant strides from its factory foundation towards becoming a vertically integrated pharmaceutical company. In the beginning, its revenue stream was primarily from the factory. It has now diversified into 3 main revenue streams of Private Market sales, Contract Manufacturing sales and Government Tender. Specpharm provides an ideal base through which to drive Simeka’s healthcare strategy rollout. Simeka invested in Specpharm during 2014 through the acquisition of a 42% shareholding in the company.